General Information of This Drug (ID: DMDRT0E)

Drug Name
Idoxuridine   DMDRT0E
Synonyms
Emanil; Herpesil; Herpidu; Idossuridina; Iododeoxyuridine; Kerecide; Ophthalmadine; Synmiol; ID2; LT00440811; SKF 14287; Dendrid (TN); HERPLEX (TN); Herpe-Gel; Herpes-Gel; Iododeoxyuridine-125I; Oftan-IDU; SK&F 14287; SK&F-14287; Idoxuridine (JP15/USP/INN); Idoxuridine [USAN:INN:BAN:JAN]; 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil; 1-(2-deoxypentofuranosyl)-4-hydroxy-5-iodopyrimidin-2(1H)-one; 1-(2-deoxypentofuranosyl)-5-iodopyrimidine-2,4(1h,3h)-dione; 1-(4-Hydroxy-5-hydroxymethyltetrahydrofuran-2-yl)-5-iodo-1H-pyrimidine-2,4-dione; 1-[(2R,4R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[(2S,4S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione; 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 1.beta.-D-2'-Deoxyribofuranosyl-5-iodouracil; 1beta-D-2'-Deoxyribofuranosyl-5-iodouracil; 2'-Deoxy-5-(iodo-125I)uridine; 2'-deoxy-5-(125i)iodouridine; 5-(125-I)-Iodo-2-deoxyuridine; 5-I-2'-dUrd; 5-Iododesoxyuridine; 5IdU
Indication
Disease Entry ICD 11 Status REF
Herpes simplex virus infection 1F00 Approved [1]
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Idoxuridine + Idarubicin DC4HST5 Idarubicin Glioblastoma? (Cell Line: T98G) [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 014169.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.